Publications by authors named "Tetyana T Tsugorka"
Article Synopsis
- Acute pancreatitis (AP) is a serious inflammatory condition with no specific treatments available; it's triggered by factors like elevated calcium levels and ATP depletion.
- A new drug, CM4620, currently in Phase 2b trials, shows promise as a CRAC channel inhibitor for AP but requires high concentrations for effectiveness, which could cause side effects.
- Combining lower doses of CM4620 with galactose, a natural carbohydrate, significantly enhances protective effects against cell damage and inflammation in AP models, suggesting a synergistic approach to treatment.
